High throughput formulation screening for global aggregation behaviors of three monoclonal antibodies.

Global aggregation behaviors of three distinct monoclonal antibodies were characterized by high throughput, multiassay analysis. First, extensive screening of formulations was performed using both incubation at elevated temperature and differential thermal scanning. In incubation studies, formulation conditions representing native favored, native favored but with particulate formation, unfolding with slow aggregation, and fast aggregation with or without phase separation were mapped across a wide range of pH and ionic strength. The sample types or aggregation kinetic scenarios were classified based on fluorescence spectroscopy, light scattering, and micron particle count. Furthermore, apparent melting point was determined for each formulation condition by differential thermal scanning. The global aggregation behaviors and their apparent melting points together highlight the common underlying aggregation pathways and kinetics for the three antibodies. Overall, incorporating multistage aggregation mechanisms in multivariate data analysis provides valuable insights to what and how high throughput techniques can be implemented. Understanding global aggregation behaviors is a key element toward development of rational screening approach.

[1]  Christopher J Roberts,et al.  Comparative effects of pH and ionic strength on protein-protein interactions, unfolding, and aggregation for IgG1 antibodies. , 2010, Journal of pharmaceutical sciences.

[2]  Linda O Narhi,et al.  High throughput thermostability screening of monoclonal antibody formulations. , 2010, Journal of pharmaceutical sciences.

[3]  Babatunde A. Ogunnaike,et al.  Multi-variate approach to global protein aggregation behavior and kinetics: effects of pH, NaCl, and temperature for alpha-chymotrypsinogen A. , 2010, Journal of pharmaceutical sciences.

[4]  Brian T. Cunningham,et al.  A Method for Identifying Small-Molecule Aggregators Using Photonic Crystal Biosensor Microplates , 2009, JALA.

[5]  William F. Weiss,et al.  Characterization of high-molecular-weight nonnative aggregates and aggregation kinetics by size exclusion chromatography with inline multi-angle laser light scattering. , 2009, Journal of pharmaceutical sciences.

[6]  Jared S. Bee,et al.  Monoclonal antibody interactions with micro- and nanoparticles: adsorption, aggregation, and accelerated stress studies. , 2009, Journal of pharmaceutical sciences.

[7]  Hanns-Christian Mahler,et al.  Protein aggregation: pathways, induction factors and analysis. , 2009, Journal of pharmaceutical sciences.

[8]  L. Narhi,et al.  A critical review of analytical methods for subvisible and visible particles. , 2009, Current pharmaceutical biotechnology.

[9]  I. Shimada,et al.  High‐throughput screening of optimal solution conditions for structural biological studies by fluorescence correlation spectroscopy , 2009, Protein science : a publication of the Protein Society.

[10]  C. Roberts,et al.  Lumry-Eyring nucleated-polymerization model of protein aggregation kinetics. 2. Competing growth via condensation and chain polymerization. , 2009, The journal of physical chemistry. B.

[11]  Steven Kozlowski,et al.  Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. , 2009, Journal of pharmaceutical sciences.

[12]  William F Weiss,et al.  Principles, approaches, and challenges for predicting protein aggregation rates and shelf life. , 2009, Journal of pharmaceutical sciences.

[13]  Joon-Seok Lee,et al.  High-throughput analysis of Alzheimer's beta-amyloid aggregation using a microfluidic self-assembly of monomers. , 2009, Analytical chemistry.

[14]  G. Senisterra,et al.  High throughput methods of assessing protein stability and aggregation. , 2009, Molecular bioSystems.

[15]  M. Dragunow,et al.  High throughput quantification of mutant huntingtin aggregates , 2008, Journal of Neuroscience Methods.

[16]  Wim Jiskoot,et al.  Extrinsic Fluorescent Dyes as Tools for Protein Characterization , 2008, Pharmaceutical Research.

[17]  Christopher J Roberts,et al.  Non‐native protein aggregation kinetics , 2007, Biotechnology and bioengineering.

[18]  F. Niesen,et al.  The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability , 2007, Nature Protocols.

[19]  A. Fink,et al.  Fluorescence as a method to reveal structures and membrane-interactions of amyloidogenic proteins. , 2007, Biochimica et biophysica acta.

[20]  Christopher J Roberts,et al.  A Lumry-Eyring nucleated polymerization model of protein aggregation kinetics: 1. Aggregation with pre-equilibrated unfolding. , 2007, The journal of physical chemistry. B.

[21]  C. Roberts,et al.  Non-native aggregation of alpha-chymotrypsinogen occurs through nucleation and growth with competing nucleus sizes and negative activation energies. , 2007, Biochemistry.

[22]  Robert Gurny,et al.  High throughput screening of protein formulation stability: practical considerations. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[23]  Robert Gurny,et al.  Detection and characterization of protein aggregates by fluorescence microscopy. , 2007, International journal of pharmaceutics.

[24]  Randall J Mrsny,et al.  Formulation and delivery issues for monoclonal antibody therapeutics. , 2006, Advanced drug delivery reviews.

[25]  Dong Jin Kim,et al.  A high-throughput screen for compounds that inhibit aggregation of the Alzheimer's peptide. , 2006, ACS chemical biology.

[26]  M. Lindgren,et al.  Detection and characterization of aggregates, prefibrillar amyloidogenic oligomers, and protofibrils using fluorescence spectroscopy. , 2005, Biophysical journal.

[27]  Steven J Shire,et al.  Challenges in the development of high protein concentration formulations. , 2004, Journal of pharmaceutical sciences.

[28]  C. Dobson,et al.  Rationalization of the effects of mutations on peptide andprotein aggregation rates , 2003, Nature.

[29]  John F. Carpenter,et al.  Physical Stability of Proteins in Aqueous Solution: Mechanism and Driving Forces in Nonnative Protein Aggregation , 2003, Pharmaceutical Research.

[30]  Christopher M. Dobson,et al.  Kinetic partitioning of protein folding and aggregation , 2002, Nature Structural Biology.

[31]  R. Murphy,et al.  A mathematical model of the kinetics of beta-amyloid fibril growth from the denatured state. , 2001, Biophysical journal.

[32]  R. Carrotta,et al.  Conformational characterization of oligomeric intermediates and aggregates in β‐lactoglobulin heat aggregation , 2001, Protein science : a publication of the Protein Society.

[33]  V. Uversky,et al.  Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism. , 2001, Biochemistry.

[34]  A. Fink Protein aggregation: folding aggregates, inclusion bodies and amyloid. , 1998, Folding & design.

[35]  H. Levine Stopped-flow kinetics reveal multiple phases of thioflavin T binding to Alzheimer beta (1-40) amyloid fibrils. , 1997, Archives of biochemistry and biophysics.

[36]  H J Berger,et al.  Practical considerations in the production, purification, and formulation of monoclonal antibodies for immunoscintigraphy and immunotherapy. , 1989, Seminars in nuclear medicine.

[37]  Yi Li Global non-native aggregation behavior for alpha-chymotrypsinogen A , 2009 .

[38]  Wei Wang,et al.  Antibody structure, instability, and formulation. , 2007, Journal of pharmaceutical sciences.

[39]  T. Arakawa,et al.  Theory of protein solubility. , 1985, Methods in enzymology.